Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2023 Jan 20

PMID 36659914

Authors

Abdallah Damin Abukhalil

Ola Ali

Asmaa Saad

Hiba Falana

Nimeh Al-Shami

Hani A Naseef

Abdullah Rabba

Affiliations

Soon will be listed here.

Abstract

Background: Proton pump inhibitors (PPIs) are the most effective agents for managing acid-related disorders. However, inappropriate prescribing of PPIs is becoming an issue of concern.

Objective: This study aimed to assess the appropriate utilization of PPIs in terms of indication, dose, frequency, and route of administration during admission and discharge. Furthermore, direct costs associated with inappropriate PPI use were calculated.

Methods: A descriptive cross-sectional study was conducted at the internal medicine department of a tertiary hospital in Palestine from January 1, 2021, to June 30, 2021. The medical records of patients aged 18 years or older, hospitalized for 48 hours or more, and receiving oral or intravenous (IV) PPIs during their stay were collected and evaluated for the appropriateness of PPIs prescribed according to clinical guidelines.

Results: Of 262 patients, 80.2% had an appropriate indication for prophylaxis (67.6%) or treatment (12.6%). A total of 230 patients were prescribed IV pantoprazole.182 (79.1%) had an appropriate indication, whereas 122/182 (67%) received IV PPI instead of oral without an appropriate indication. Of the 32 patients who received 20 mg of oral omeprazole, 28 (87.5%) had an appropriate indication, dose, and route of administration, whereas 16/28 (57.1%) had an inappropriate frequency. At discharge, 32.5% of patients were discharged with unnecessary PPI prescriptions. The total direct cost of inappropriate PPI Indications and route of administration in 188 patients over six months was $1518.

Conclusion: This study showed that most patients received a PPI for an appropriate indication with the correct dose. However, a high prevalence of inappropriate IV pantoprazole administration was observed, resulting in the highest costs, demonstrating the importance of correctly ordering IV medications. Adherence to clinical guidelines, such as those of the American College of Gastroenterology (ACG), will improve the appropriateness of PPI prescribing, prevent complications, and reduce healthcare costs.

Citing Articles

Predictive Factors Associated with Inappropriate Intravenous Proton Pump Inhibitors Use in Hospitalized Patients: A Case-Control Study.

Khoury N, Stepensky D, Abu Freha N, Mahamid M, Khoury T, Mari A Medicina (Kaunas). 2025; 61(1).

PMID: 39858992 PMC: 11767144. DOI: 10.3390/medicina61010010.

Drug Therapy Problems Identified by Clinical Pharmacists at a General Surgery Ward of an Academic Referral Hospital in Jordan.

Al Fahmawi H, Albsoul-Younes A, Saleh M, Abu-Abeeleh M, Kasabri V Ther Clin Risk Manag. 2024; 20:619-631.

PMID: 39280637 PMC: 11402340. DOI: 10.2147/TCRM.S465128.

Prevalence and Safety of Prescribing PPIs with Clopidogrel in Palestine.

Abukhalil A, Al Sheikh T, Muallem S, Al-Shami N, Naseef H Patient Prefer Adherence. 2023; 17:749-759.

PMID: 36970301 PMC: 10038207. DOI: 10.2147/PPA.S404139.

References

Nasser S, Nassif J, Dimassi H . Clinical and cost impact of intravenous proton pump inhibitor use in non-ICU patients. World J Gastroenterol. 2010; 16(8):982-6. PMC: 2828603. DOI: 10.3748/wjg.v16.i8.982. View

Fallone C, Chiba N, Veldhuyzen Van Zanten S, Fischbach L, Gisbert J, Hunt R . The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016; 151(1):51-69.e14. DOI: 10.1053/j.gastro.2016.04.006. View

Nachnani J, Bulchandani D, Moormeier J, Foxworth J . Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients. J Hosp Med. 2009; 4(8):E10-4. DOI: 10.1002/jhm.492. View

Chey W, Leontiadis G, Howden C, Moss S . ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2):212-239. DOI: 10.1038/ajg.2016.563. View

Korayem G, Alkanhal R, Almass R, Alkhunaizan S, Alharthi G, Bin Sheraim N . Patients, Prescribers, and Institutional Factors Associated with Inappropriate Use of Acid Suppressive Therapy in Medical Wards: An Experience of a Single-Center in Saudi Arabia. Int J Gen Med. 2021; 14:5079-5089. PMC: 8416456. DOI: 10.2147/IJGM.S328914. View

Katz P, Dunbar K, Schnoll-Sussman F, Greer K, Yadlapati R, Spechler S . ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2021; 117(1):27-56. PMC: 8754510. DOI: 10.14309/ajg.0000000000001538. View

Gralnek I, Stanley A, Morris A, Camus M, Lau J, Lanas A . Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021. Endoscopy. 2021; 53(3):300-332. DOI: 10.1055/a-1369-5274. View

Zink D, Pohlman M, Barnes M, Cannon M . Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005; 21(10):1203-9. DOI: 10.1111/j.1365-2036.2005.02454.x. View

Laine L, Barkun A, Saltzman J, Martel M, Leontiadis G . ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol. 2021; 116(5):899-917. DOI: 10.14309/ajg.0000000000001245. View

10.

Strand D, Kim D, Peura D . 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2016; 11(1):27-37. PMC: 5221858. DOI: 10.5009/gnl15502. View

11.

Souaid C, Maalouf R, Hallit S, Akiki B, Dagher E . Relevance of proton pump inhibitors prescriptions in a tertiary care hospital in Lebanon. Arab J Gastroenterol. 2020; 21(3):194-198. DOI: 10.1016/j.ajg.2020.07.008. View

12.

Sachs G, Shin J, Howden C . Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23 Suppl 2:2-8. DOI: 10.1111/j.1365-2036.2006.02943.x. View

13.

Abukhalil A, AbuKhdeir L, Hamed M, Al Shami N, Naseef H, Aiesh B . Characteristics, Risk Factors, and Prevalence of Among Hospitalized Patients in a Tertiary Care Hospital in Palestine. Infect Drug Resist. 2021; 14:4681-4688. PMC: 8591314. DOI: 10.2147/IDR.S333985. View

14.

Bischoff L, Faraco L, Machado L, Bialecki A, Almeida G, Becker S . INAPPROPRIATE USAGE OF INTRAVENOUS PROTON PUMP INHIBITORS AND ASSOCIATED FACTORS IN A HIGH COMPLEXITY HOSPITAL IN BRAZIL. Arq Gastroenterol. 2021; 58(1):32-38. DOI: 10.1590/S0004-2803.202100000-07. View

15.

Yibirin M, de Oliveira D, Valera R, Plitt A, Lutgen S . Adverse Effects Associated with Proton Pump Inhibitor Use. Cureus. 2021; 13(1):e12759. PMC: 7887997. DOI: 10.7759/cureus.12759. View

16.

Grube R, May D . Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007; 64(13):1396-400. DOI: 10.2146/ajhp060393. View

17.

Boghossian T, Rashid F, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C . Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017; 3:CD011969. PMC: 6464703. DOI: 10.1002/14651858.CD011969.pub2. View

18.

Mohzari Y, Alsaegh A, Asdaq S, Al Shanawani S, Albraiki A, Bagalb A . The Pattern of Intravenous Proton-Pump Inhibitor Utilization at an Academic Medical Center in Riyadh, Saudi Arabia. J Res Pharm Pract. 2021; 9(3):151-154. PMC: 7808177. DOI: 10.4103/jrpp.JRPP_20_62. View

19.

Gamelas V, Salvado V, Dias L . Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol. 2019; 26(2):114-120. PMC: 6454380. DOI: 10.1159/000488506. View

20.

Graham D, Tansel A . Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency. Clin Gastroenterol Hepatol. 2017; 16(6):800-808.e7. PMC: 6913203. DOI: 10.1016/j.cgh.2017.09.033. View